At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers want to see if it is practical to give immunotherapy before kidney cancer surgery. The people in this study have no evidence of cancer spread in other parts of their body. Researchers also want to see if this treatment causes any delays in surgery. Immunotherapy is treatment that boosts the body's natural defenses to fight cancer.
-
Germ cell tumors (GCTs) include ovarian teratomas and testicular cancers. The standard treatment for "low-risk" GCTs includes complete removal by surgery followed by chemotherapy with cisplatin, bleomycin, and etoposide, unless the patient is a young child, in which case careful observation may be adequate. GCTs are considered "standard risk" if the patient is under age 25 at diagnosis, the tumor was not completely removed during surgery or has spread to other parts of the body, or proteins in the blood called tumor markers are elevated. The standard treatment for standard-risk GCTs includes chemotherapy with cisplatin, bleomycin, and etoposide followed by surgery, followed by more chemotherapy if needed.
-
A Study of the Voro Urologic Scaffold to Prevent Urinary Incontinence After Prostate Removal SurgeryProstate removal (prostatectomy), a treatment for prostate cancer, can cause urinary incontinence (the inability to control the flow of urine). People experience urinary incontinence in the days immediately following surgery, which can reduce quality of life. Most people experience urinary incontinence for several weeks to months after surgery, but it can last longer.
- A Phase 2 Study of Zongertinib in People With HER2-Positive Advanced Solid Tumors
Full Title Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-Label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2 Mutated or Overexpressed/Amplified Solid Tumours
Purpose
Researchers want to see if zongertinib is safe and works well to treat advanced solid tumors. The people in this study have solid tumors that metastasized (spread). The tumors contain an abnormal HER2 protein (mutation) or too much HER2 (overexpression/amplification). HER2 promotes the growth of cancer cells.
Zongertinib blocks the HER2 protein and may help slow or stop the growth of your cancer. Researchers think zongertinib may work better and cause fewer or milder side effects than other HER2-blocking therapies. Zongertinib is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have a metastatic solid tumor with HER2 overexpression/amplification or mutation which cannot be cured with existing treatments.
- Have recovered from the serious side effects of prior therapies before taking zongertinib.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Alison Schram’s office at 646-888-5388.
Protocol
24-282Phase
Phase II (phase 2)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06581432ClinicalTrials.gov
-
Researchers want to find the best dose of LY4066434 when given alone and with other drugs to treat solid tumors. The people in this study have cancer that has spread (advanced) or cannot be removed with surgery (inoperable). These include colorectal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, and other solid tumors.
-
Researchers are seeking the best doses of vorasidenib and temozolomide to treat glioma and assessing how well they work together. The people in this study have grade 4 gliomas with a mutation (change) in the IDH1 or IDH2 gene. These mutations can cause cancer cells to multiply and spread.
-
Metaiodobenzylguanidine (MIBG) is a substance taken up specifically by neuroblastoma, pheochromocytoma, or paraganglioma tumor cells. MIBG can be combined with radioactive iodine (<sup>131</sup>I) in the laboratory to form the radioactive compound <sup>131</sup>I-MIBG. The <sup>131</sup>I-MIBG compound concentrates more in cancer cells than in normal cells. It may therefore deliver more radiation directly to cancer cells while sparing normal organs.
-
ABBV-324 is a type of drug called an antibody-drug conjugate (ADC). ADCs are composed of an antibody made from a specific cell line chemically linked to a drug. The antibody binds to specific proteins on certain types of cells, including cancer cells. The linked drug enters these cells and destroys them, with a lower risk of harming other cells. ABBV-324 is given intravenously (by vein).
-
Chemotherapy for lymphoma can cause side effects, especially in people age 65 and older and those with other health problems. Researchers want to see if adding the immunotherapy drugs glofitamab, polatuzumab, and obinutuzumab to treatment can reduce the amount of chemotherapy needed. The people in this study have diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. Their cancer has not yet been treated.
- A Phase 1-2 Study of BNT326 Alone or With BNT327 in People With Advanced Solid Tumors
Full Title A Phase I/II, Open-Label, Adaptive Two-Part trial to Evaluate the Safety, Efficacy, Optimal Dose, and Pharmacokinetics of BNT326 as Monotherapy and in Combination with Cancer Immunotherapies in Participants with Advanced Solid Tumors
Purpose
Researchers are assessing BNT326 alone or with BNT327 to treat advanced solid tumors. The people in this study have cancers that have come back or keep growing after treatment, including:
- Melanoma of the skin
-
Non-small cell lung cancer
- Bile duct cancer (cholangiocarcinoma)
- Liver cancer (hepatocellular carcinoma)
- Kidney cancer (renal cell carcinoma)
- Uterine (endometrial) cancer
- Pancreatic cancer
- Neuroendocrine cancer
- HER2-negative breast cancer
BNT326 is a type of drug called an antibody-drug conjugate (ADC). ADCs are made of a monoclonal antibody linked to a drug. The antibody binds to a protein on cancer cells called HER3, which plays a role in cancer cell growth. It then releases the anti-cancer drug to kill the cancer cell. By destroying these cells, BNT326 may help slow or stop the growth of your cancer. It is given intravenously (by vein).
BNT327 binds to one protein on the surface of cancer cells and another on the surface of immune cells. It may strengthen your immune system’s ability to fight cancer cells by activating your own cells to destroy your tumor. BNT327 is given intravenously. Only people with melanoma or breast cancer may be offered the combination of BNT326 and BNT327.
Who Can Join
To join this study, there are a few conditions. You must:
- Have one of the advanced cancers listed above.
- Have recovered from the serious side effects of prior treatments before getting the study therapy.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call 646-888-4226.
Protocol
25-247Phase
Phase I/II (phases 1 and 2 combined)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT07070232ClinicalTrials.gov